executive sells $115,000 in stock
– An executive at () recently sold company stock totaling $115,000, according to a recent regulatory filing.
The transaction involved the sale of 5,000 shares of common stock at a price of $23.0 per share. The sale was executed on by , who holds the position of at the company. The sale occurred near the stock’s 52-week high of $23.15, following a remarkable 112% gain over the past year that has pushed the company’s market capitalization to $3.5 billion.
Footnote in the filing indicated that .
This report is based on information from the SEC Form 4 filing. For investors seeking deeper insights, InvestingPro offers comprehensive analysis including 11 additional ProTips and a detailed Pro Research Report covering ADPT’s financial health and growth prospects.
In other recent news, reported strong financial results for the first quarter of 2026, with revenue reaching $70.9 million, surpassing analyst expectations of $60.89 million. This revenue growth was primarily driven by the company’s Minimal Residual Disease business. Additionally, Adaptive Biotechnologies announced plans to offer $250 million in convertible senior notes due 2031, with an option for initial purchasers to acquire an additional $37.5 million in notes. The company intends to conduct this offering through a private placement to qualified institutional buyers. Furthermore, Adaptive Biotechnologies revealed its intention to separate its Minimal Residual Disease and Immune Medicine units, with a strategic decision expected by the end of 2026. BTIG reiterated a Buy rating on the company’s stock, maintaining a price target of $22.00, following these business updates. The firm highlighted the upsized convertible notes offering, which increased from $250 million to $300 million, and the planned business separation as key factors in its assessment.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
investment News